You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Teriflunomide

Showing 1 - 25 of 85
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HAM/TSP Trial run by the NINDS (Teriflunomide)

Recruiting
  • HAM/TSP
  • Teriflunomide
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Mechanistic Studies of Teriflunomide in RRMS

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Teriflunomide
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Multiple Sclerosis Trial (Frexalimab, Teriflunomide, Placebo infusion)

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Nov 15, 2023

Microglial Activation inMS Patient Cohort at Risk of Progression

Active, not recruiting
  • Multiple Sclerosis
    • Turku, Finland Proper, Finland
      Turku PET Centre
    May 31, 2022

    Multiple Sclerosis Trial in San Diego, Canada (Teriflunomide (HMR1726))

    Recruiting
    • Multiple Sclerosis
    • Teriflunomide (HMR1726)
    • San Diego, California
    • +1 more
    Jan 12, 2022

    Multiple Sclerosis Trial in Moscow (BCD-132, Teriflunomide)

    Recruiting
    • Multiple Sclerosis
    • BCD-132
    • Teriflunomide
    • Moscow, Russian Federation
      State Budgetary Healthcare Institution of the Moscow Region M.F.
    May 18, 2022

    Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

    Completed
    • Multiple Sclerosis
    • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
    • Prague, Czechia
      IMPULS Endowment Fund
    Mar 7, 2023

    Teriflunomide Observational Effectiveness Study

    Completed
    • Relapsing Remitting Multiple Sclerosis
    • Teriflunomide
    • Montréal, Quebec, Canada
      CHUM
    Aug 17, 2021

    Relationship Between Oral DMT Burden and Adherence in MS

    Enrolling by invitation
    • Multiple Sclerosis
    • Adherence, Medication
    • Melbourne, Victoria, Australia
      Monash University
    Aug 28, 2022

    Teriflunomide on Cognitive and Vocational Outcomes in Multiple

    Completed
    Has Results
    • Multiple Sclerosis
      • Buffalo, New York
        Buffalo General Hospital, D3
      Aug 31, 2021

      Multiple Sclerosis Trial in Ramat Gan (COVID-19 vaccination)

      Recruiting
      • Multiple Sclerosis
      • COVID-19 vaccination
      • Ramat Gan, Israel
        Sheba Medical Center
      Oct 6, 2021

      Multiple Sclerosis Trial in Nizhny Novgorod (BCD-132, 125 mg, Teriflunomide, Placebo)

      Active, not recruiting
      • Multiple Sclerosis
      • BCD-132, 125 mg
      • +3 more
      • Nizhny Novgorod, Russian Federation
        State Budgetary Healthcare Institution of Nizhny Novgorod region
      Sep 6, 2021

      Relapsing Multiple Sclerosis Trial in Worldwide (Remibrutinib, Teriflunomide)

      Recruiting
      • Relapsing Multiple Sclerosis
      • Fullerton, California
      • +38 more
      Aug 12, 2022

      Multiple Sclerosis, Pharmacokinetics Trial in Gothenburg (Teriflunomide 14 MG)

      Recruiting
      • Multiple Sclerosis, Pharmacokinetics
      • Teriflunomide 14 MG
      • Gothenburg, Vastra Gotaland, Sweden
        MS Centre
      Mar 16, 2021

      Relapsing Multiple Sclerosis Trial in Worldwide (Remibrutinib, Teriflunomide)

      Recruiting
      • Relapsing Multiple Sclerosis
      • Hanford, California
      • +41 more
      Aug 5, 2022

      Celiac Disease Trial in Oslo (Teriflunomide Oral Tablet)

      Recruiting
      • Celiac Disease
      • Teriflunomide Oral Tablet
      • Oslo, Norway
        Dept of Gastroenterology
      Apr 16, 2021

      Disease Activity in Patients Treated With Teriflunomide

      Completed
      • Multiple Sclerosis, Relapsing-Remitting
      • Teriflunomide
      • Montréal, Quebec, Canada
        Department of Pathology
      Mar 23, 2021

      Teriflunomide Tecfidera LMCE

      Completed
      • Tecfidera
      • Teriflunomide
      • Dimethyl Fumarate
      • Teriflunomide
      • Buffalo, New York
        Buffalo Neuroimaging Analysis Center
      Jan 4, 2021

      Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

      Completed
      Has Results
      • Relapsing Multiple Sclerosis (RMS)
      • Ublituximab
      • +3 more
      • Phoenix, Arizona
      • +12 more
      Nov 11, 2021

      Teriflunomide Elimination, Healthy Volunteers Trial in Tampa (teriflunomide, Colestipol)

      Terminated
      Has Results
      • Teriflunomide Elimination
      • Healthy Volunteers
      • Tampa, Florida
        USF Carol and Frank Morsani Center for Advanced Healthcare
      Apr 1, 2020

      Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

      Completed
      Has Results
      • Relapsing Multiple Sclerosis (RMS)
      • Ublituximab
      • +3 more
      • Carlsbad, California
      • +13 more
      Nov 5, 2021

      Long-Term Safety of Vumerity and Tecfidera in Multiple Sclerosis

      Not yet recruiting
      • Multiple Sclerosis
      • Diroximel Fumarate
      • +2 more
      • (no location specified)
      Mar 2, 2023

      Relapsing Multiple Sclerosis Trial in Worldwide (fenebrutinib, teriflunomide, )

      Recruiting
      • Relapsing Multiple Sclerosis
      • Cullman, Alabama
      • +138 more
      Jan 5, 2023

      Multiple Sclerosis Trial in Worldwide (ponesimod, teriflunomide)

      Completed
      Has Results
      • Multiple Sclerosis
      • Carlsbad, California
      • +161 more
      Jan 24, 2022

      Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)

      Active, not recruiting
      • Relapsing Multiple Sclerosis
      • Cullman, Alabama
      • +275 more
      Nov 7, 2022